Researchers looked at a small group of 14 patients who had cancer that had spread to their bones. They treated these patients with two specific radioactive medications called 225Ac-DOTA-IBA and 177Lu-DOTA-IBA. The goal was to see if these drugs could reduce pain and improve how patients felt physically.
After the first round of treatment, 92.9% of patients reported feeling less pain. Additionally, many patients saw improvements in their overall physical status and ability to perform daily tasks. Imaging scans also showed that about half of the patients had a positive response to the treatment, while others had stable disease or minor changes.
The study noted that the medications were well tolerated, with no severe side effects reported. However, the researchers emphasize that this is a preliminary study involving a very small number of people. Because the sample size is so limited, these findings should not be taken as proof that the drugs work for everyone or that they are ready for widespread use.
Readers should understand that while the results look encouraging, more research is needed to fully understand the benefits and risks. This early evidence is a step forward, but it does not yet mean doctors will start using these treatments as a standard option for all patients.
